ES3014017T3 - Inhibitor of map kinase interacting serine/threonine kinase 1 (mnk1) and map kinase interacting serine/threonine kinase 2 (mnk2), cancer therapy and therapeutic combinations - Google Patents

Inhibitor of map kinase interacting serine/threonine kinase 1 (mnk1) and map kinase interacting serine/threonine kinase 2 (mnk2), cancer therapy and therapeutic combinations Download PDF

Info

Publication number
ES3014017T3
ES3014017T3 ES20739952T ES20739952T ES3014017T3 ES 3014017 T3 ES3014017 T3 ES 3014017T3 ES 20739952 T ES20739952 T ES 20739952T ES 20739952 T ES20739952 T ES 20739952T ES 3014017 T3 ES3014017 T3 ES 3014017T3
Authority
ES
Spain
Prior art keywords
cancer
pharmaceutically acceptable
acceptable salt
veterinary
pyrazolo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES20739952T
Other languages
English (en)
Spanish (es)
Inventor
Y Cajal Agüeras Santiago Ramon
Stefan Hümmer
Vives Josep Castellvi
Saez Elena Martinez
Bilbao José Ignacio Borrell
Closa Jordi Teixido
Tejedor Roger Estrada
Petit Elisabeth Bou
Camara Vicente Peg
Carrillo Pedro Jesus Guijarro
Margalef Anna Santamaria
Robles Joan Morote
Cabrera Leticia Suarez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut Químic de Sarrià
Centro de Investigación Biomédica en Red
Fundació Institut de Recerca Hospital Universitari Vall d'Hebron
Original Assignee
Institut Químic de Sarrià
Centro de Investigación Biomédica en Red
Fundació Institut de Recerca Hospital Universitari Vall d'Hebron
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut Químic de Sarrià, Centro de Investigación Biomédica en Red, Fundació Institut de Recerca Hospital Universitari Vall d'Hebron filed Critical Institut Químic de Sarrià
Application granted granted Critical
Publication of ES3014017T3 publication Critical patent/ES3014017T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES20739952T 2019-07-10 2020-07-09 Inhibitor of map kinase interacting serine/threonine kinase 1 (mnk1) and map kinase interacting serine/threonine kinase 2 (mnk2), cancer therapy and therapeutic combinations Active ES3014017T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES201930643 2019-07-10
PCT/EP2020/069459 WO2021005183A1 (en) 2019-07-10 2020-07-09 Inhibitor of map kinase interacting serine/threonine kinase 1 (mnk1) and map kinase interacting serine/threonine kinase 2 (mnk2), cancer therapy and therapeutic combinations

Publications (1)

Publication Number Publication Date
ES3014017T3 true ES3014017T3 (en) 2025-04-16

Family

ID=71607975

Family Applications (1)

Application Number Title Priority Date Filing Date
ES20739952T Active ES3014017T3 (en) 2019-07-10 2020-07-09 Inhibitor of map kinase interacting serine/threonine kinase 1 (mnk1) and map kinase interacting serine/threonine kinase 2 (mnk2), cancer therapy and therapeutic combinations

Country Status (5)

Country Link
US (1) US20220257571A1 (enExample)
EP (1) EP3996710B1 (enExample)
JP (1) JP7536243B2 (enExample)
ES (1) ES3014017T3 (enExample)
WO (1) WO2021005183A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11958832B1 (en) 2023-10-12 2024-04-16 King Faisal University 2-alkoxy[4,3:6,3-terpyridine]-3-carbonitriles as antimicrobial compounds
US11926611B1 (en) 2023-11-24 2024-03-12 King Faisal University 2-(2-ethoxyethoxy)-6-phenyl-4,4′-bipyridine-3-carbonitrile as an antimicrobial compound
US12071407B1 (en) 2023-12-05 2024-08-27 King Faisal University 6-(4-hydroxyphenyl)-2-(2-ethoxyethoxy)-4-(4-methoxyphenyl)nicotinonitrile as an antimicrobial compound
US11970451B1 (en) 2023-12-07 2024-04-30 King Faisal University 6-(3-hydroxyphenyl)-2-methoxy-4-(3-methylphenyl)nicotinonitrile as an antimicrobial compound

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2160780A1 (de) 1971-12-08 1973-06-14 Basf Ag Pyridino-pyrazole
US20100113415A1 (en) 2008-05-29 2010-05-06 Rajapakse Hemaka A Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer
WO2011019780A1 (en) 2009-08-11 2011-02-17 Bristol-Myers Squibb Company Azaindazoles as btk kinase modulators and use thereof
CN105531279A (zh) 2013-07-08 2016-04-27 拜耳制药股份公司 取代的吡唑并吡啶胺
AU2016252038B2 (en) * 2015-04-20 2021-08-12 Effector Therapeutics, Inc. Inhibitors of immune checkpoint modulators for use in treating cancer and infections

Also Published As

Publication number Publication date
WO2021005183A1 (en) 2021-01-14
JP7536243B2 (ja) 2024-08-20
JP2022539840A (ja) 2022-09-13
US20220257571A1 (en) 2022-08-18
EP3996710B1 (en) 2025-01-22
EP3996710A1 (en) 2022-05-18
EP3996710C0 (en) 2025-01-22

Similar Documents

Publication Publication Date Title
Zhang et al. Polo-like kinase 1 inhibitors in human cancer therapy: development and therapeutic potential
US12233052B2 (en) Tetrahydro-pyrido[3,4-b]indole estrogen receptor modulators and uses thereof
Song et al. Cdc2-like kinases: structure, biological function and therapeutic targets for diseases
EP3996710B1 (en) Inhibitor of map kinase interacting serine/threonine kinase 1 (mnk1) and map kinase interacting serine/threonine kinase 2 (mnk2), cancer therapy and therapeutic combinations
Maira et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity
Lei et al. Inhibition of MGMT-mediated autophagy suppression decreases cisplatin chemosensitivity in gastric cancer
Cao et al. Cap-dependent translation initiation factor, eIF4E, is the target for Ouabain-mediated inhibition of HIF-1α
Yeh et al. Flavopereirine induces cell cycle arrest and apoptosis via the AKT/p38 MAPK/ERK1/2 signaling pathway in human breast cancer cells
CA2891938A1 (en) Combination therapy
JP2009506068A (ja) Ｈｉｆ阻害剤
Stone et al. Inhibitors of cell cycle kinases: recent advances and future prospects as cancer therapeutics
Lineham et al. Synergistic effects of inhibiting the MNK-eIF4E and PI3K/AKT/mTOR pathways on cell migration in MDA-MB-231 cells
BR112019018723A2 (pt) compostos de imidazo[4,5-c]quinolin-2-ona deuterada e seu uso no tratamento do câncer
Li et al. Discovery, synthesis, and evaluation of novel dual inhibitors of a vascular endothelial growth factor receptor and poly (ADP-ribose) polymerase for BRCA wild-type breast cancer therapy
Wang et al. Bryostatin-1 inhibits cell proliferation of hepatocarcinoma and induces cell cycle arrest by activation of GSK3β
Chen et al. PCC0208023, a potent SHP2 allosteric inhibitor, imparts an antitumor effect against KRAS mutant colorectal cancer
CA3174972A1 (en) Co-treatment with cdk4/6 and cdk2 inhibitors to suppress tumor adaptation to cdk2 inhibitors
Sharma et al. Assessment of structural and activity-related contributions of various PIM-1 kinase inhibitors in the treatment of leukemia and prostate cancer
Roolf et al. Novel isoquinolinamine and isoindoloquinazolinone compounds exhibit antiproliferative activity in acute lymphoblastic leukemia cells
Jin et al. APIO-EE-9 is a novel Aurora A and B antagonist that suppresses esophageal cancer growth in a PDX mouse model
Ramón y Cajal Agüeras et al. Inhibitor of map kinase interacting serine/threonine kinase 1 (mnk1) and map kinase interacting serine/threonine kinase 2 (mnk2), cancer therapy and therapeutic combinations
Cao et al. Role and therapeutic potential of P2X7 receptor in lung cancer progression
Mattiuzzo Pharmacological studies of novel antitumoral compounds
Li Effects and Mechanisms of Methuosis Defined Through the Use of Indole-Based Chalcone Compounds in Human Glioblastoma Cells
AU2014280224A1 (en) Combination of a imidazopyridazine derivative and a mitotic agent for the treatment of cancer